Introduction
Trovafloxacin (CP-99,219) is a novel trifluoroquinolone characterized chemically as a naphthyridone substituted with a fluorine atom at the C-6 position, a 3-azabicyclo[3. 1.0] hexyl moiety at the C-7 position and a 2,4-fluorophenyl group at the N-1 position. 1 As such, trovafloxacin is closely related to tosufloxacin, a compound that is more active against Gram-positive and anaerobic bacteria than are other members of this class of antimicrobial agents, such as ciprofloxacin and ofloxacin. 2 In this study, we have determined the in-vitro activity of trovafloxacin against a wide range of clinically important species, including Chlamydia spp., Mycobacterium spp., Mycoplasma spp. and Ureaplasma urealyticum, and compared its activity with that of ciprofloxacin and ofloxacin.
Materials and methods

Antimicrobial agents
The following antimicrobial agents were studied: ciprofloxacin (Bayer plc, Newbury, UK); nalidixic acid (Sigma, Poole, UK); ofloxacin (Hoechst Marion Roussel, Romainville, France) and trovafloxacin (Pfizer Ltd, Sandwich, UK). Stock solutions were prepared according to the manufacturers' recommendations.
Bacterial isolates
The majority of isolates included in the study were derived from clinical specimens recently examined in the Department of Clinical Microbiology, University College Hospital. Additional strains were included that had been collected from European centres during 1993-1994, and kept at 70 C at GR Micro Ltd, in a protective matrix of undiluted horse serum. respectively; the inoculum was again 10 4 cfu/1 L spot. Susceptibility of anaerobes was determined in WilkinsChalgren agar containing saponin-lysed horse blood at a final concentration of 5% (v/v) with an inoculum of 10 5 cfu/1 L spot following NCCLS guidelines for anaerobic organisms. 4 The activity of test antibacterial agents against Legionella spp. was assessed in buffered yeast extract agar containing Legionella Growth Supplement (Unipath Ltd, Basingstoke, UK) and saponin-lysed horse blood at a final concentration of 5% (v/v) and with an inoculum of 10 4 cfu/1 L spot. Chlamydia spp. were tested by a cell culture incorporation technique in McCoy cells treated with cycloheximide for Chlamydia pneumoniae or with iododeoxyuridine for Chlamydia trachomatis. 5 MICs for isolates of Mycoplasma spp. and Ureaplasma urealyticum were determined by an incorporation technique in supplemented PPLO broth (Difco Laboratories Ltd, West Molesey, UK) with an inoculum of 10 5 colony-forming units. 5 Middlebrook 7H10 agar (Difco) supplemented with OADC Enrichment (Difco) at a final concentration of 10% (v/v) was used to determine the susceptibility of Mycobacterium spp.
Determination of antimicrobial susceptibility
Results
In general, trovafloxacin was two-to four-fold less active against isolates of Enterobacteriaceae than ciprofloxacin and similar to, or two-fold more active than ofloxacin, depending on species. The activity of trovafloxacin was reduced proportionately against isolates showing reduced susceptibility to ciprofloxacin and ofloxacin (Table I) . Data for nalidixic acid are included in this and other tables to demonstrate that quinolone-resistant strains were included in the test population of some species. Trovafloxacin was generally half as active as ciprofloxacin against Pseudomonas aeruginosa (MIC 50 0.5 mg/L; MIC 90 8 mg/L).
In common with ofloxacin and ciprofloxacin, trovafloxacin exhibited potent activity against isolates of Legionella pneumophila, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis and Vibrio chlolerae (Table I) , includinglactamase-producing strains of some of these species.
Trovafloxacin demonstrated potent activity against methicillin-susceptible and methicillin-resistant isolates of Staphylococcus spp. and was eight to 16 times more active than ofloxacin or ciprofloxacin against fluoroquinoloneresistant strains (Table II) . Trovafloxacin was 16-fold more active than ciprofloxacin or ofloxacin against isolates of Streptococcus pneumoniae, including strains resistant to penicillin. Trovafloxacin was generally two to four times more active than either ofloxacin or ciprofloxacin against other Gram-positive species, including -haemolytic and -haemolytic streptococci, Enterococcus faecalis, Listeria monocytogenes, Corynebacterium diphtheriae and Corynebacterium jeikeium (Table II) .
Chlamydia trachomatis SA 2 f and C. pneumoniae TW 183 were generally eight to 16 times more susceptible to trovafloxacin than to either ofloxacin or ciprofloxacin. Trovafloxacin was highly active against Mycoplasma pneumoniae, Mycoplasma hominis and U. urealyticum; this activity was generally eight to 16 times greater than that of either ofloxacin or ciprofloxacin (Table II) . Trovafloxacin was poorly active against Mycobacterium tuberculosis and isolates of the Mycobacterium aviumintracellulare complex (Table II) .
Trovafloxacin was the most potent of the fluoroquinolones tested against obligate anaerobes (Table III) , being particularly active against Bacteroides fragilis, Peptostreptococcus spp., and Clostridium perfringens. Isolates of Clostridium difficile were generally less susceptible to trovafloxacin and to the other fluoroquinolones.
Discussion
The results of this study are in broad agreement with those of others confirming the extended antibacterial spectrum of t r o v a floxacin to include important Gram-positive and 'atypical' pathogens of the lower respiratory tract such as S . p n e u m o n i a e, M. pneumoniae and C. pneumoniae.
1 , 6 -8 P r e v ious studies have also demonstrated that trovafloxacin has good in-vitro activity against anaerobes. Trovafloxacin is rapidly absorbed after oral administration in healthy volunteers with a mean time to peak serum concentration of approximately 1 h. 10 Other pharmacokinetic features of trovafloxacin are its long elimination half-life, and superior penetration of pulmonary tissue compared with ciprofloxacin, and hence its suitability for use in the treatment of respiratory tract infections.
11
Clinically, ofloxacin and ciprofloxacin have been used with great success for the treatment of a wide range of infections caused by bacteria that have been shown to be susceptible to these fluoroquinolones in vitro. 2 Clinical efficacy, however, is dependent not only on in-vitro activity against appropriate organisms but also on the ability of the agent to penetrate specific body compartments. The in-vitro antibacterial activity of trovafloxacin demonstrated in the present study together with its pharmacokinetic profile 10,11 indicate that trovafloxacin, too, may have an important clinical role in the treatment of a wide range of bacterial infections, including those of the upper and lower respiratory tract, urogenital tract, blood, skin and soft tissues. 
